BI 764532
Boehringer Ingelheim
[]
4: the main goal of this trial is to determine the maximum tolerated dose (mtd) of bi 764532. other objectives include safety, tolerability, pk/pd, and preliminary efficacy. #asco23 #clinicaltrials 
🫁Pneumo-Onco🩺 Chef de Pôle de Méd à Orientation Onco 🏥 @CHToulonLaSeyne 🔬Conseil Scientifique @IFCTLung / Pdte du 3C VarOuest 👉🏼#HopitalPublic #LungCancer